跳转至内容
Merck

S-018

Supelco

舒芬太尼-D5标准液 溶液

100 μg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

登录查看公司和协议定价


About This Item

经验公式(希尔记法):
C22D5H25N2O2S
分子量:
391.58
EC號碼:
分類程式碼代碼:
41116107
NACRES:
NA.24

等級

certified reference material

品質等級

形狀

liquid

特點

Snap-N-Spike®/Snap-N-Shoot®

包裝

ampule of 1 mL

製造商/商標名

Cerilliant®

drug control

Narcotic Licence Schedule A (Switzerland); estupefaciente (Spain); Decreto Lei 15/93: Tabela IA (Portugal)

濃度

100 μg/mL in methanol

技術

gas chromatography (GC): suitable
liquid chromatography (LC): suitable

應用

forensics and toxicology

形式

single component solution

儲存溫度

2-8°C

SMILES 字串

[2H]C([2H])(C)C(=O)N(c1ccccc1)C2(CCN(CCc3cccs3)CC2)COC

InChI

1S/C22H30N2O2S/c1-3-21(25)24(19-8-5-4-6-9-19)22(18-26-2)12-15-23(16-13-22)14-11-20-10-7-17-27-20/h4-10,17H,3,11-16,18H2,1-2H3/i3D2

InChI 密鑰

GGCSSNBKKAUURC-SMZGMGDZSA-N

一般說明

Sufentanil is a short acting synthetic opioid analgesic used as a painkiller during medical operations. This stable-labeled internal standard is suitable for quantitation of sufentanil levels in urine, serum, or plasma by LC/MS or GC/MS for clinical toxicology, pain prescription monitoring, forensic analysis, or isotope dilution methods. Sufentanil is sold under the trade name Sufenta.

法律資訊

CERILLIANT is a registered trademark of Merck KGaA, Darmstadt, Germany
Snap-N-Shoot is a registered trademark of Cerilliant Corporation
Snap-N-Spike is a registered trademark of Merck KGaA, Darmstadt, Germany

相關產品

产品编号
说明
价格

訊號詞

Danger

危險分類

Acute Tox. 3 Dermal - Acute Tox. 3 Inhalation - Acute Tox. 3 Oral - Flam. Liq. 2 - STOT SE 1

標靶器官

Eyes

儲存類別代碼

3 - Flammable liquids

水污染物質分類(WGK)

WGK 1

閃點(°F)

49.5 °F - closed cup

閃點(°C)

9.7 °C - closed cup


历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our 文件 section.

如需帮助,请联系 客户支持

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

Harold S Minkowitz et al.
Regional anesthesia and pain medicine, 38(2), 131-139 (2012-12-29)
A sublingual sufentanil tablet is being developed as a potential alternative to intravenous (IV) opioids for the management of postoperative pain. The objective of these studies was to evaluate the pharmacokinetics, efficacy, and safety of sublingual sufentanil tablets for postoperative
C Jeleazcov et al.
British journal of anaesthesia, 109(5), 698-706 (2012-07-27)
Target controlled infusion (TCI) with sufentanil is usually performed using the Gepts model, which was derived from patients undergoing general surgery. It is, however, known that pharmacokinetics of sufentanil can be changed during cardiopulmonary bypass (CPB). We tested whether TCI
Q L Chen et al.
Acta anaesthesiologica Scandinavica, 57(2), 236-242 (2012-08-14)
Sufentanil is widely used in clinical anaesthesia because of its protective effects against ischaemia/reperfusion injury. Diabetes mellitus elevates the activity of glycogen synthase kinase-3β (GSK-3β), thereby increasing the permeability of mitochondrial transition pore. This study investigated the role of GSK-3β
Shen Sun et al.
Journal of anesthesia, 27(1), 25-28 (2012-08-28)
We aimed to investigate the effects of pretreatment with a small dose of dexmedetomidine on the cough caused by sufentanil during anesthetic induction. Two hundred and forty patients undergoing elective gynecological surgery under general anesthesia were randomly allocated to 4
S Dango et al.
British journal of anaesthesia, 110(3), 443-449 (2012-11-16)
Although thoracic epidural analgesia (TEA) is considered the gold standard for post-thoracotomy pain relief, thoracic paravertebral block (PVB) and intrathecal opioid (ITO) administration have also been shown to be efficacious. We hypothesized that the combination of PVB and ITO provides

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系客户支持